Status:

COMPLETED

Endovenous Versus Liposomal Iron in CKD

Lead Sponsor:

Federico II University

Conditions:

Iron Deficiency Anemia

Chronic Kidney Disease

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Anemia is a common complication in patients with chronic kidney disease (CKD). In addition to erythropoietin deficiency, many studies have identified iron deficiency as a cause of anemia in CKD patien...

Eligibility Criteria

Inclusion

  • Age ≥ 18 years;
  • Signed written informed consent;
  • Glomerular filtration rate (GFR) ≤ 60 mL/min (MDRD GFR calculated according to 4 variables);
  • hemoglobin ≤ 12g/dL;
  • Ferritin ≤ 100ng/mL with transferrin saturation (TSAT) ≤ 25%;
  • If erythropoiesis stimulating agents (ESA) therapy, stable dose for at least three months;

Exclusion

  • Infectious diseases;
  • bleeding in the preceding six months;
  • History of malignancy tumor in the last 3 years;
  • Anemia case different from that resulting from CKD;
  • vitamin B12 and folate deficiency;
  • Surgery of any kind in the last three months;
  • systemic haematological disease;
  • Blood Transfusions, therapy with intravenous or oral iron in the last three months;
  • Severe liver disease / test positive for hepatitis C virus (HCV) and hepatitis B virus (HBV);
  • Abuse of alcohol and drugs in the preceding six months;
  • immunosuppressive therapy ;
  • Significant weight loss;
  • Pregnancy or breast-feeding.

Key Trial Info

Start Date :

October 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2013

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT01864161

Start Date

October 1 2011

End Date

May 1 2013

Last Update

July 24 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Federico II University

Naples, Naples, Italy, 80131